How Many Theranostics Centers Will We Need in the United States?-Reference-Cited by-同舟云学术

How Many Theranostics Centers Will We Need in the United States?

Published:2022-06 Issue:6 Volume:63 Page:805-806
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Czernin Johannes,Calais Jeremie

Publisher

Society of Nuclear Medicine

Subject

Radiology, Nuclear Medicine and imaging

Reference8 articles.

1. U.S. Food and Drug Administration (FDA). FDA approves Pluvicto for metastatic castration-resistant prostate cancer. U.S. FDA website. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pluvicto-metastatic-castration-resistant-prostate-cancer. Accessed March 28, 2022.

2. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

3. The Future of Nuclear Medicine as an Independent Specialty

4. Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial;Hofman;Lancet.,2021

5. PSMA theranostics: current landscape and future outlook;Zhang;Cancers (Basel).,2021

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ¹⁷⁷Lu-PSMA (R)Evolution in Cancer Care: Is It Really Happening?;Journal of Nuclear Medicine;2024-08-08

2. Prostate Cancer Radioligand Therapy;PET Clinics;2024-07

3. The developing role of theranostics in NETs;The Lancet;2024-06

4. Production and regulatory issues for theranostics;The Lancet Oncology;2024-06

5. Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranostics;The Lancet Oncology;2024-06